The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 6, 2009, Pages 713-718

  Sutton, B S ^a   Arias, M S ^b   Chheng, P ^b   Eang, M T ^c   Kimerling, M E ^b,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c National Center for Tuberculosis and Leprosy Control   (Cambodia)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Cost effectiveness; Human immunodeficiency virus; Intensified case finding; Isoniazid preventive therapy; Tuberculosis

Indexed keywords

ISONIAZID;

ARTICLE; CAMBODIA; CASE FINDING; CONTROLLED STUDY; DEVELOPING COUNTRY; ECONOMIC EVALUATION; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CAMBODIA; COSTS AND COST ANALYSIS; HIV INFECTIONS; HUMANS; ISONIAZID; PATIENT SELECTION; PILOT PROJECTS; PREVENTIVE HEALTH SERVICES; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 67649182887     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. World Health Organization Global tuberculosis control: surveillance, planning, financing. WHO report 2008. WHO/HTM/ TB/2008.393. Geneva, Switzerland: WHO, 2008.
2. Terris-Prestholt F, Kumaranayake L, Ginwalla R, et al. Integrating tuberculosis and HIV services for people living with HIV: costs of the Zambian ProTEST Initiative. Cost Eff Resour Alloc 2008; 6: 2.
3. Ministry of Health, Kingdom of Cambodia. National strategic plan for TB control, 2001-2005. Busan, Cambodia: National Center for Tuberculosis and Leprosy Control, 2001.
4. Joint United Nations Program on HIV/AIDS. 2006 Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS, 2006. http://data.unaids.org/pub/ GlobalReport/2006/2006-gr- ann1g-1-en.pdf Accessed March 2008.
5. National Center for HIV/AIDS, Dermatology and STDs (NCHADS). HIV Sentinel Surveillance in Cambodia, 2003. Phnom Penh, Cambodia: NCHADS, 2003.
6. World Health Organization. WHO report 2006. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/ TB/2006.362. Geneva, Switzerland: WHO, 2006.
7. World Health Organization. Recommendations of the Interim Policy on Collaborative TB-HIV Activities. Wkly Epidemiol Rec 2004; 79: 6-11.
8. Corbett E L, Charalambous S, Moloi V M, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170: 673-679. (Pubitemid 39202210)
9. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. WHO/HTM/ TB/2007.376. Geneva, Switzerland: WHO, 2007.
10. Godfrey-Faussett P, Maher D, Mukadi Y D, Nunn P, Perriëns J, Raviglione M. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ 2002; 80: 939-945. (Pubitemid 36056085)
11. Nunn P, Harries A, Godfrey-Faussett P, Gupta R, Maher D, Raviglione M. The research agenda for improving health policy, systems performance, and service delivery for tuberculosis control: a WHO perspective. Bull World Health Organ 2002; 80: 471-476. (Pubitemid 34632825)
12. Drummond M F, Sculpher M J, Torrance G W, O'Brien B J, Stoddart G L. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford University Press, 2005.
13. Gold M R, Siegel J, Russell R, et al. Cost-effectiveness in health and medicine. New York, NY, USA: Oxford University Press, 1996.
14. Russell L B, Gold M R, Siegel J E, Daniels N, Weinstein M C. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-1177. (Pubitemid 26329746)
15. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003; 1: 1. (Pubitemid 39111887)
16. Baltussen R, Adams T, Tan Torres T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization, 2003: p 329.
17. Ramsey R H. Activity-based costing for hospitals. Hosp Health Serv Adm 1994; 39: 385-396. (Pubitemid 24256489)
18. Richardson A W, Gafni A. Treatment of capital costs in evaluating health care programmes. Cost Manag 1983; 58: 26-30.
19. Hausler H P, Sinanovic E, Kumaranayake L, et al. Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 2006; 84: 528-536. (Pubitemid 44186350)
20. Bucher H C, Griffith L E, Guyatt G H, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-507.
21. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95-104.
22. Briggs A H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500. (Pubitemid 30398806)
23. Briggs A H, Gray A M. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999; 3: 1-134.
24. Aisu T, Raviglione M C, van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 1995; 9: 267-273.
25. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11: 919-925. (Pubitemid 27226416)
26. Bell J C, Rose D N, Sacks H S. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 1999; 13: 1549-1556. (Pubitemid 29396688)
27. Shrestha R K, Mugisha B, Bunnell R, et al. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis 2007; 11: 747-754. (Pubitemid 47056983)
28. Shrestha R K, Mugisha B, Bunnell R, et al. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV- infected persons in Uganda. Int J Tuberc Lung Dis 2006; 10: 656-662. (Pubitemid 43845027)
29. Kumaranayake L. The real and the nominal? Making inflationary adjustments to cost and other economic data. Health Policy Plann 2000; 15: 230-234. (Pubitemid 30330604)
30. Sinanovic E, Floyd K, Dudley L, Azevedo V, Grant R, Maher D. Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. Int J Tuberc Lung Dis 2003; 7 (Suppl 1): S56-S62. (Pubitemid 37162932)